Close menu




March 16th, 2021 | 09:40 CET

Alibaba, Desert Gold Ventures, First Majestic Silver - Don't miss the entry!

  • Investments
Photo credits: pixabay.com

Gold is a crisis currency and intended for asset protection. As people speculate an end to the pandemic due to the vaccines' positive developments, free capital is being invested in exciting boom sectors on the stock markets. Gold, on the other hand, is dull. But watch out! Just looking at the debt levels of most countries gives the first warning. Currently, there are excellent entry opportunities in the precious yellow metal. Do not miss the entry!

time to read: 3 minutes | Author: Stefan Feulner
ISIN: US01609W1027 , CA25039N4084 , CA32076V1031

Table of contents:


    Desert Gold Ventures - On track

    The gold price high since summer at just under USD 2,070 has been followed by a consolidation phase lasting several months, which at times led below the USD 1,700 mark. The price turned around at the critical support zone of USD 1,680. Currently, a bottoming out around the USD 1,720 is taking place. Should this hold, the adjustment should be over for the time being. Gold mines have lost more than the price. They act as a lever in both directions. It's time to get your foot in the door on promising mining stocks. One interesting investment is Desert Gold Ventures.

    The gold explorer with a stock market valuation of just under EUR 15 million has halved in value since the all-time high in the gold price, but fundamentally things are going more than well. A few weeks ago, the Company reported on the most extensive drilling program in its history, covering 20,000 meters at the SMSZ project in Mali. Already this year, the breakthrough should be achieved on the project, as there are several promising targets at an advanced stage in the correct regional environment. The project is located between the Fekola gold mine of B2Gold, the Gounkoto and Loulo mines of Barrick Gold and the Sadiola and Yatela mines of the consortium AngloGold Ashanti, Iamgold and the government of Mali in the immediate vicinity.

    First Majestic Silver- The chart wants to go up!

    We have already seen a new all-time high for First Majestic Silver this year. However, this had less fundamental reasons. In the course of the Reddit community's "WallStreetBets" silver campaign, the value exploded to the equivalent of almost EUR 22.00, only to collapse again to EUR 13.00 a short time later. The EUR 13.00 mark now served as an important support line in the past few days and was successfully defended. A break above the EUR 15.00 mark would result in a price target of EUR 17.00.

    On the corporate side, there are currently quite positive reports. The Company announced the acquisition of the Jerritt Canyon mine in Nevada. The mine was paid for by Sprott Mining for USD 470 million in First Majestic shares plus 5 million First Majestic share purchase warrants. The mine has produced over 9.5 million ounces of gold in its 40-year production history. The mine is currently operated as an underground mine.

    Alibaba - Uncertainty weighs!

    An investment in the Chinese Internet giant Alibaba remains uncertain at the moment. After the slump last year, when the subsidiary Ant Group's IPO was briefly canceled and Company founder Jack Ma disappeared for several weeks, the price was able to hold above the EUR 200.00 mark after the crash from over EUR 270.00 to a low of EUR 170.00. Currently, the chart picture has clouded significantly due to the renewed slide to EUR 190.00. One reason for the weak performance is the Chinese government's pressure on Internet giants such as Baidu, Tencent and Alibaba. The first fines have now been imposed on the companies. Although the penalties are "only" just under USD 80,000, they are more of a warning shot. In this way, the government is forcing control over its domestic Internet companies. Monopolistic practices and potential violations of consumer rights go against the grain of the policy.

    According to the Wall Street Journal, Alibaba could be in for a tough time. The competition authorities may impose new record fines of more than USD 800 million. As the WSJ reported, the authorities accuse the online group of prohibiting merchants on its platform from using other online companies. Moreover, another blow is the resignation of Ant Financial's CEO, Simon Hu. The latter handed over his key last week "for personal reasons." We would currently refrain from investing, in addition to the technical chart situation, for the reasons mentioned above.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read